Showing results (341-350 of 352) with videos related to
Sort By:
Pageof 36
Journal of the National Comprehensive Cancer Network : JNCCN|June 10, 2017
Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyRobert J Motzer, Eric Jonasch, Neeraj Agarwal, et al.Cancer|December 26, 2022
Development and validation of a recursive partitioning analysis-based pretreatment decision-making tool identifying ideal candidates for spine stereotactic body radiation therapyRoman O Kowalchuk, Trey C Mullikin, Marcus Florez, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2018
Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)Brigette B Y Ma, Wan-Teck Lim, Boon-Cher Goh, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2017
Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone ResistanceManish Kohli, Yeung Ho, David W Hillman, et al.CBE Life Sciences Education|April 4, 2025
Highlighting Counterstereotypical Scientists in Undergraduate Life Science CoursesRobin A Costello, Sharday N Ewell, Paula E Adams, et al.Journal of the National Comprehensive Cancer Network : JNCCN|June 19, 2015
Testicular Cancer, Version 2.2015Robert J Motzer, Eric Jonasch, Neeraj Agarwal, et al.Journal of the National Comprehensive Cancer Network : JNCCN|February 19, 2015
Kidney cancer, version 3.2015Robert J Motzer, Eric Jonasch, Neeraj Agarwal, et al.Journal of the National Comprehensive Cancer Network : JNCCN|September 4, 2020
NCCN Guidelines Insights: Kidney Cancer, Version 1.2021Robert J Motzer, Eric Jonasch, Shawna Boyle, et al.Journal of the National Comprehensive Cancer Network : JNCCN|November 7, 2019
NCCN Guidelines Insights: Kidney Cancer, Version 2.2020Robert J Motzer, Eric Jonasch, M Dror Michaelson, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 26, 2017
A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisoneL Wang, S M Dehm, D W Hillman, et al.Pageof 36